{"took":5392,"timed_out":false,"_shards":{"total":5,"successful":5,"failed":0},"hits":{"total":7,"max_score":0.35930452,"hits":[{"_index":"beers","_type":"2015","_id":"11","_score":0.35930452,"_source":{"category-drugs":"Nifedipine, immediate release","organ-system":"Cardiovascular","rationale":"Potential for hypotension; risk of precipitating myocardial ischemia","recommendation":"Avoid","quality-of-evidence":"High","strength-of-recommendation":"Strong","evidence":"Furberg 1995, Nifedipine package insert, Pahor 1995, Psaty 1995a, Psaty 1995b"}},{"_index":"beers","_type":"2015","_id":"6","_score":0.35199422,"_source":{"category-drugs":"Peripheral alpha-1 blockers: Doxazosin, Prazosin, Terazosin","organ-system":"Cardiovascular","rationale":"High risk of orthostatic hypotension; not recommended as routine treatment for hypertension; alternative agents have superior risk/benefit profile","recommendation":"Avoid use as an antihypertensive","quality-of-evidence":"Moderate","strength-of-recommendation":"Strong","evidence":"ALLHAT 2000, Aronow 2011"}},{"_index":"beers","_type":"2015","_id":"8","_score":0.26455426,"_source":{"category-drugs":"Disopyramide","organ-system":"Cardiovascular","rationale":"Disopyramide is a potent negative inotrope and therefore may induce heart failure in older adults; strongly anticholinergic; other antiarrhythmic drugs preferred","recommendation":"Avoid","quality-of-evidence":"Low","strength-of-recommendation":"Strong","evidence":"Fuster 2006, Disopyramide package insert"}},{"_index":"beers","_type":"2015","_id":"7","_score":0.2623265,"_source":{"category-drugs":"Central alpha blockers: Clonidine, Guanabenz, Guanfacine, Methyldopa, Reserpine (>0.1 mg/d)","organ-system":"Cardiovascular","rationale":"High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension","recommendation":"Avoid clonidine as first-line antihypertensive. Avoid others as listed.","quality-of-evidence":"Low","strength-of-recommendation":"Strong","evidence":"Aronow 2011, Methyldopa package insert, Reserpine package insert"}},{"_index":"beers","_type":"2015","_id":"9","_score":0.2116434,"_source":{"category-drugs":"Dronedarone","organ-system":"Cardiovascular","rationale":"Worse outcomes have been reported in patients taking dronedarone who have permanent atrial fibrillation or severe or recently decompensated heart failure","recommendation":"Avoid in individuals with permanent atrial fibrillation or severe or recently decompensated heart failure","quality-of-evidence":"High","strength-of-recommendation":"Strong","evidence":"Connolly 2011, FDA Drug Safety 2011, Hohnloser 2009, Korber 2008, Dronedarone package insert â€“revised"}},{"_index":"beers","_type":"2015","_id":"12","_score":0.18518797,"_source":{"category-drugs":"Amiodarone","organ-system":"Cardiovascular","rationale":"Amiodarone is effective for maintaining sinus rhythm but has greater toxicities than other antiarrhythmics used in atrial fibrillation; it may be reasonable first-line therapy in patients with concomitant heart failure or substantial left ventricular hypertrophy if rhythm control is preferred over rate control.","recommendation":"Avoid amiodarone as first-line therapy for atrial fibrillation unless the patient has heart failure or substantial left ventricular hypertrophy.","quality-of-evidence":"High","strength-of-recommendation":"Strong","evidence":"Fuster 2006, ACC/AHA 2006 guideline"}},{"_index":"beers","_type":"2015","_id":"10","_score":0.1058217,"_source":{"category-drugs":"Digoxin","organ-system":"Cardiovascular","rationale":"Use in atrial fibrillation: should not be used as a first-line agent in atrial fibrillation, because more-effective alternatives exist and it may be associated with increased mortality. Use in heart failure: questionable effects on risk of hospitalization and may be associated with increased mortality in older adults with heart failure; in heart failure, higher dosages not associated with additional benefit and may increase risk of toxicity. Decreased renal clearance of digoxin may lead to increased risk of toxic effects; further dose reduction may be necessary in those with Stage 4 or 5 chronic kidney disease.","recommendation":"Avoid as first-line therapy for atrial fibrillation. Avoid as first-line therapy for heart failure. If used for atrial fibrillation or heart failure, avoid dosages >0.125 mg/d.","quality-of-evidence":"Atrial fibrillation: moderate. Heart failure: low. Dosage >0.125 mg/d: moderate.","strength-of-recommendation":"Atrial fibrillation: strong. Heart failure: strong. Dosage >0.125 mg/d: strong.","evidence":"2015 Criteria: Use in atrial fibrillation: Al-Khatib 2013, Turakhia 2014, Whitbeck 2013, Gheorghiade 2013a, Gheorghiade 2013b, Friberg 2010, Mulder 2014, Ambrosy 2014, National PBM Bulletin 2014. Use in heart failure: Freeman 2013. From previous criteria: Adams 2002, Ahmed 2007, Rathore 2003"}}]}}